Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 14;15(1):64.
doi: 10.1186/s13613-025-01480-w.

High flow nasal therapy versus noninvasive ventilation for AECOPD with acute hypercapnic respiratory failure: a meta-analysis of randomized controlled trials

Jinlv Qin #  1 , Guizuo Wang #  2 , Yixing Liao #  3 , Wenli Shang #  2 , Dong Han  4
Affiliations
Review

High flow nasal therapy versus noninvasive ventilation for AECOPD with acute hypercapnic respiratory failure: a meta-analysis of randomized controlled trials

Jinlv Qin et al. Ann Intensive Care. .

Abstract

Background: Guidelines recommend the use of noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic acute respiratory failure (ARF). It is unclear whether HFNC is noninferior to NIV in terms of the rate of tracheal intubation or mortality. This meta-analysis aimed to compare the efficacy of HFNC and NIV in patients with AECOPD and hypercapnic ARF.

Methods: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of hypercapnic AECOPD with HFNC, compared with NIV, were reviewed. Estimated effects of included studies were pooled as risk ratios (RRs), with 95% confidence intervals (CIs).

Results: Four RCTs (enrolling 486 patients) met the inclusion criteria. There was no statistically significant difference in all-cause mortality (RR 0.97, 95% CI 0.56 to 1.68), and intubation rate (RR 1.67, 95% CI 0.99 to 2.83) between the two groups. The treatment switch rate (RR 2.60, 95% CI 1.54 to 4.38) and treatment failure rate (RR 1.64, 95% CI 1.04 to 2.60) were significantly lower in NIV groups.

Conclusions: Compared with NIV, HFNC was not associated with increased mortality and intubation rate. More patients receiving HFNC oxygen therapy experienced treatment failure and switched to NIV, which may mask the fact that HFNC is inferior to NIV in patients with AECOPD and hypercapnic ARF.

Keywords: COPD; HFNC; Mortality; NIV.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: None of the authors has a competing interests to declare.

Figures

Fig. 1
Fig. 1
Flow chart for selection of studies
Fig. 2
Fig. 2
Assessment on risk of bias for included RCTs
Fig. 3
Fig. 3
Forest plot assessing the efficacy of HFNC versus NIV on A all-cause mortality, B intubation rates, C treatment switch rates, and D treatment failure rates
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the global burden of disease study 2019. BMJ Clin Res. 2022;378: e069679. - PMC - PubMed
    1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report gold executive summary. Am J Res Critical Care medicine. 2017;195(5):557–82. - PubMed
    1. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Res J. 2017;50(2):1602426. - PubMed
    1. Bruni A, Garofalo E, Cammarota G, et al. High flow through nasal cannula in stable and exacerbated chronic obstructive pulmonary disease patients. Rev Recent Clin Trials. 2019;14(4):247–60. - PubMed
    1. Pisani L, Vega ML. Use of nasal high flow in stable COPD: rationale and physiology. COPD. 2017;14(3):346–50. - PubMed

LinkOut - more resources